ULISSE BIOMED S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.195 EUR | -0.42% |
|
+2.58% | -27.79% |
| 09/05 | Ulisse Biomed, Sbaizero resigns as independent director | AN |
| 03/05 | Ulysses Biomed reduces loss in 2023; NFP is positive | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2023 * | 341K 371K 30.93M | Sales 2024 * | 1.42M 1.55M 129M | Capitalization | 25.88M 28.16M 2.35B |
|---|---|---|---|---|---|
| Net income 2023 * | -1M -1.09M -90.7M | Net income 2024 * | - 0 0 | EV / Sales 2023 * | 69.5 x |
| Net cash position 2023 * | 2.19M 2.38M 199M | Net cash position 2024 * | 2.36M 2.57M 214M | EV / Sales 2024 * | 16.6 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 9 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 92.9% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.42% | ||
| 1 week | +2.58% | ||
| Current month | -2.85% | ||
| 1 month | -13.41% | ||
| 3 months | -23.40% | ||
| 6 months | -25.31% | ||
| Current year | -27.79% |
1 week
1.16
1.22
1 month
1.051.39
Current year
1.051.90
1 year
1.052.52
3 years
0.977.55
5 years
0.977.55
10 years
0.977.55
| Managers | Title | Age | Since |
|---|---|---|---|
Bruna Marini
FOU | Founder | 39 | - |
Rudy Ippodrino
FOU | Founder | - | - |
Matteo Petti
CEO | Chief Executive Officer | 41 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Luigi Colombo
BRD | Director/Board Member | 60 | - |
Matteo Petti
CEO | Chief Executive Officer | 41 | - |
Laura Amadesi
BRD | Director/Board Member | 56 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/24/15 | 1.195 | -0.42% | 12 000 |
| 14/24/14 | 1.2 | +0.84% | 12,000 |
| 13/24/13 | 1.19 | +1.71% | 7,000 |
| 10/24/10 | 1.17 | -4.10% | 21,000 |
| 09/24/09 | 1.22 | +4.72% | 16,000 |
Real-time Borsa Italiana, May 15, 2024 at 09:14 pm IST
More quotes
Ulisse Biomed Spa is an Italy-based company engaged in the healthcare biotech sector. The Company focuses on creating new and transformative diagntostic platforms and products. It creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.
Trading Rating
Investor Rating
ESG Refinitiv
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.79% | 28M | |
| +28.96% | 49.18B | |
| +1.34% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.95% | 26.09B | |
| -22.06% | 18.71B | |
| +7.88% | 13.26B | |
| +32.35% | 12.32B | |
| -0.19% | 11.99B |
- Stock Market
- Equities
- UBM Stock
